Cover Image

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis

Control of cutaneous leishmaniasis (CL) in the Americas is dependent on chemotherapy with parenteral pentavalent antimonials. High rates of treatment failure urge the search for predictive and prognostic markers of therapeutic responsiveness. In this study, we aimed to identify biomarkers of therape...

Full description

Saved in:

Bibliographic Details
Main Authors:	Deninson Alejandro Vargas (Author), Miguel Dario Prieto (Author), Alvaro José Martínez-Valencia (Author), Alexandra Cossio (Author), Karl E. V. Burgess (Author), Richard J.S. Burchmore (Author), María Adelaida Gómez (Author)
Format:	Book
Published:	Frontiers Media S.A., 2019-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
by: Maria Del Mar Castro, et al.
Published: (2017)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
by: Brandon A Berger, et al.
Published: (2017)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
by: Mohamad Javad Yazdanpanah, et al.
Published: (2011)

Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
by: Olga Lucía Fernández, et al.
Published: (2024)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
by: Jairo E Perez-Franco, et al.
Published: (2016)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
by: Jamile Lago, et al.
Published: (2023)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
by: Jamile Lago, et al.
Published: (2023)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
by: Jamile Lago, et al.
Published: (2023)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
by: Mohammad Reza Aflatoonian, et al.
Published: (2019)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
by: Nayara C Brito, et al.
Published: (2019)

Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.
by: Isabel M Vincent, et al.
Published: (2012)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
by: Carla Oliveira-Ribeiro, et al.
Published: (2021)

First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report
by: Omid MOZAFARI, et al.
Published: (2016)

Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.
by: Cristian Valencia, et al.
Published: (2012)

Evaluation of Correlation between the in Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran
by: Nafiseh Ghobakhloo, et al.
Published: (2017)

Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis.
by: Alvaro J Martínez-Valencia, et al.
Published: (2017)

Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
by: Olga Lucía Fernández, et al.
Published: (2014)

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
by: Amir Javadi, et al.
Published: (2022)

Pharmacometabolomics by NMR in Oncology: A Systematic Review
by: Nuria Gómez-Cebrián, et al.
Published: (2021)

Meglumine antimonate resistance: first alarm in region
by: S. Brutyan, et al.
Published: (2020)

Parasitological Confirmation and Analysis of Leishmania Diversity in Asymptomatic and Subclinical Infection following Resolution of Cutaneous Leishmaniasis.
by: Mariana Rosales-Chilama, et al.
Published: (2015)

Pharmacometabolomics may be the next stamp in the pharmacogenetic passport
by: Frank Klont, et al.
Published: (2024)

Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication
by: Jingai Jian, et al.
Published: (2023)

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.
by: María F García-Bustos, et al.
Published: (2021)

Pharmacometabolomics informs viromics towards precision medicine
by: Aggeliki Balasopoulou, et al.
Published: (2016)

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers
by: Filipa Amaro, et al.
Published: (2022)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016)

Pharmacogenetics-Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid
by: N. A. Shnayder, et al.
Published: (2023)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
by: Giuseppe Corona, et al.
Published: (2023)

Leishmaniose cutânea com desfecho fatal durante tratamento com antimonial pentavalente American cutaneous leishmaniasis with fatal outcome during pentavalent antimoniate treatment
by: Meiri Vanderlei Nogueira de Lima, et al.
Published: (2007)

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.
by: Cesar Miranda-Verastegui, et al.
Published: (2009)

Sustainable production of radionuclidically pure antimony-119
by: Aeli P. Olson, et al.
Published: (2024)

The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy.
by: Ines Lakhal-Naouar, et al.
Published: (2015)

Proteomic analysis of the effects of thioctic acid within meglumine thioctate
by: I. I. Torshin, et al.
Published: (2017)

Acute erythroid toxicity in visceral leishmaniasis: A rare complication of antimonial therapy
by: Sharma Sunita, et al.
Published: (2008)

Exploring a tristhione scorpionate ligand as a suitable chelator for the theranostic pair antimony-119 and antimony-117
by: Lorraine Gaenaelle Gé, et al.
Published: (2024)

Estudo clínico randomizado comparando antimoniato de meglumina, pentamidina e anfotericina B para o tratamento da leishmaniose cutânea ocasionada por Leishmania guyanensis A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis
by: Leandro Ourives Neves, et al.
Published: (2011)

The role of excipients of trometamolum and meglumine in the formation of biopharmaceutical properties of medicinal products of various pharmacites
by: T. A. Palchevska, et al.
Published: (2021)